

# CONCERT GENETIC TESTING: GENERAL APPROACH TO GENETIC AND MOLECULAR TESTING

---

Reference Number: LA.CP.CG.07  
Date of Last Revision 06/24

[Coding implications](#)  
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## OVERVIEW

Genetic testing refers to the use of technologies that identify genetic variation, which include genomic, transcriptional, proteomic, and epigenetic alterations, for the prevention, diagnosis, and treatment of disease. [Germline](#) variants or mutations are defined as genetic alterations that occur within the germ cells (egg or sperm), such that the alteration becomes incorporated into the DNA of every cell in the body, which can be passed down to future offspring. Somatic variants or mutations are defined as genetic alterations that occur at the level of the cell, such that the alteration is only in the DNA of that cell/group of cells and it cannot be passed down to offspring.

Some conditions, such as sickle cell disease, are caused by a single [germline](#) pathogenic variant, which can be passed down through generations. Other conditions, such as diabetes and heart disease, are more complex. These complex conditions are referred to as [multifactorial conditions](#), meaning that there is a combination of different inherited and environmental factors. Environmental factors, such as nutrition, exercise, weight, smoking, drinking alcohol, and medication use may influence the observable characteristics of the condition.

Solid tumor and hematologic malignancy genetic testing aims to identify somatic oncogenic mutations in cancer, which offers the potential to provide treatment options beyond the current standard of care.

Oncology [algorithmic tests](#) combine biomarkers and/or clinical data into an algorithm to generate a disease risk assessment, prognostic result, or clinical recommendation for treatment. Testing methodologies commonly include Gene Expression Profiling (GEP), which analyzes messenger RNA (mRNA) typically of multiple genes simultaneously, multimarker serum analysis, single-nucleotide variant testing, plasma-based proteomic analysis, and incorporation of other clinical data into test outputs.

Targeted mutation testing (or known familial variant analysis) is the process of analyzing one single pathogenic or likely pathogenic (P/LP) variant in one gene. Generally, this type of testing is recommended when there is a known P/LP variant in an individual's close relative.

Importantly, an individual meeting criteria for broader testing (i.e. full gene or multi-gene panel testing) based on clinical history should have broader testing performed. Of note, if a variant of

unknown significance (VUS) is detected in an individual, it is not recommended that family members also be tested for the VUS, unless the VUS is reclassified to a pathogenic or likely pathogenic variant.

Genetic counseling is recommended for patients who are at risk for inherited disorders and who are interested in undergoing genetic testing. Interpreting the results of genetic tests and understanding risk factors can be challenging. Genetic counseling helps in the understanding of the potential impacts of genetic testing, including possible effects the test results could have on the individual or their family members. Genetic counseling may alter the utilization of genetic testing substantially and has been shown to reduce inappropriate testing and should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

**The general approach to genetic testing criteria is intended for the evaluation of genetic testing that has not been more specifically addressed by other criteria.**

## OTHER RELATED POLICIES

This policy document provides criteria for the general approach to genetic testing for any genetic testing not specifically addressed in other related policies. Please refer to the following documents for specific criteria:

- *Genetic Testing: Noninvasive Prenatal Screening*
- *Genetic Testing: Prenatal Diagnosis (via amniocentesis, CVS, or PUBS) and Pregnancy Loss*
- *Genetic Testing: Prenatal and Preconception Carrier Screening*
- *Genetic Testing: Hereditary Cancer Susceptibility*
- *Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies*
- *Oncology: Cancer Screening*
- *Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy)*
- *Oncology: Algorithmic Testing*
- *Oncology: Cytogenetics*
- *Genetic Testing: Pharmacogenetics*
- *Genetic Testing: Exome and Genome Sequencing for the Diagnosis of Genetic Disorders*
- *Genetic Testing: Epilepsy, Neurodegenerative, and Neuromuscular Disorders*
- *Genetic Testing: Hematologic Conditions (non-cancerous)*
- *Genetic Testing: Gastroenterologic Conditions (non-cancerous)*
- *Genetic Testing: Cardiac Disorders*
- *Genetic Testing: Aortopathies and Connective Tissue Disorders*
- *Genetic Testing: Hearing Loss*
- *Genetic Testing: Eye Disorders*
- *Genetic Testing: Immune, Autoimmune, and Rheumatoid Disorders*
- *Genetic Testing: Kidney Disorders*
- *Genetic Testing: Lung Disorders*
- *Genetic Testing: Metabolic, Endocrine, and Mitochondrial Disorders*
- *Genetic Testing: Dermatologic Conditions*

- *Genetic Testing: Skeletal Dysplasia and Rare Bone Disorders*

[back to top](#)

## CRITERIA

It is the policy of Louisiana Healthcare Connections that the specific genetic testing noted below is **medically necessary** when meeting the related criteria:

### GENERAL APPROACH TO GENETIC TESTING

#### General Criteria for Known Familial Variant Analysis for a Genetic Condition

The criteria below is intended for the evaluation of genetic testing that has not been more specifically addressed by criteria in another policy.

- I. Targeted mutation analysis for a known familial variant for a genetic condition is considered **medically necessary** when:
  - A. The member/enrollee is 18 years or older (if the condition is [adult-onset](#)), **AND**
  - B. The member/enrollee has a [close relative](#) with a known pathogenic or likely pathogenic variant causing the condition, **AND**
  - C. An association between the gene and disease has been established
- II. Targeted mutation analysis for a known familial variant of uncertain significance is considered **investigational**.
- III. Targeted mutation analysis for a known familial variant for a genetic condition is considered **investigational** for all other indications.

[back to top](#)

#### General Criteria for Targeted Carrier Screening

The criteria below is intended for the evaluation of genetic testing that has not been more specifically addressed by criteria in another policy.

Targeted carrier screening is defined as a test that screens for a known mutation in one gene associated with a specific genetic condition.

- I. Carrier screening for a genetic disorder may be considered **medically necessary** when:
  - A. The member/enrollee is considering pregnancy or is currently pregnant, **AND**

- B. The genetic disorder is a recessive condition with a [childhood](#) onset, **AND**
- C. One of the following:
  - 1. The member/enrollee has a [close relative](#) with a known pathogenic or likely pathogenic variant associated with the disorder, **OR**
  - 2. The member/enrollee's reproductive partner is a carrier for the genetic disorder, **OR**
  - 3. The member/enrollee or the member/enrollee's reproductive partner are members of a population known to have a carrier rate of 1% or higher for the genetic condition, **OR**
  - 4. The member/enrollee or the member/enrollee's reproductive partner has a [first- or second-degree relative](#) who is affected with the genetic disorder.
- II. Carrier screening for a genetic disorder is considered **investigational** when the member/enrollee does not meet any criteria above.

[back to top](#)

## General Criteria for Single Gene or Multigene Panel Analysis

The criteria below is intended for the evaluation of genetic testing that has not been more specifically addressed by criteria in another policy.

- I. Genetic testing for a genetic condition via single-gene or multigene panel analysis may be considered **medically necessary** when:
  - A. The member/enrollee displays clinical features of the suspected genetic condition, **AND**
  - B. The diagnosis remains uncertain after appropriate clinical evaluation and other standard laboratory tests/imaging/etc. have been performed, **AND**
  - C. The test has [clinical validity](#), as demonstrated by accurately determining diagnostic, prognostic or clinical information for a disease, **AND**
  - D. The test has [clinical utility](#), as demonstrated by at least one of the following:
    - 1. The test will determine if a particular therapeutic intervention is effective (or ineffective) in the member/enrollee, or if a particular intervention may be harmful, **OR**
    - 2. The test will directly impact the clinical management, **OR**
    - 3. The test will determine prognosis, **OR**

4. The test will provide or refine estimates of the natural history, recurrence risk, or the predicted course of the genetic condition, **AND**
  - E. There is no known pathogenic or likely pathogenic familial variant for the genetic condition for which targeted variant analysis would be more appropriate, **AND**
  - F. Non-genetic causes for the member/enrollee's clinical features have been ruled out (e.g., pathogens, drug toxicity, environmental factors, etc.), **AND**
  - G. An association with the gene or multigene panel and disease has been established
- II. Genetic testing in an individual under the age of 18 for an [adult-onset condition](#) is considered **not medically necessary**.
  - III. Genetic testing via single-gene or multigene panel analysis is considered **investigational** or **not medically necessary** when the above criteria are not met.

[back to top](#)

## General Criteria for Tumor Biomarker Analysis

The criteria below is intended for the evaluation of genetic testing that has not been more specifically addressed by criteria in another policy.

- I. General tumor biomarker analysis\* is **medically necessary** when:
  - A. The member/enrollee has a confirmed neoplasm and/or malignancy, **AND**
  - B. The test has [clinical validity](#), as demonstrated by accurately determining diagnostic, prognostic or clinical information for a disease, **AND**
  - C. The test has [clinical utility](#), as demonstrated by at least one of the following:
    1. The test will determine if a particular therapeutic intervention is effective (or ineffective) in the member/enrollee, or if a particular intervention may be harmful, **OR**
    2. The test will directly impact the clinical management, **OR**
    3. The test will determine prognosis, **OR**
    4. The test will provide or refine estimates of the natural history, recurrence risk, or the predicted course of the genetic condition, **AND**
  - D. Testing is being performed in a Clinical Laboratory Improvement Amendments (CLIA) approved laboratory.
- II. General tumor biomarker analysis is considered **investigational** for all other indications.

\*See the Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies policy for criteria regarding common mutation analysis for tumor testing.

[back to top](#)

### General Criteria for Oncology Algorithmic Tests

The criteria below is intended for the evaluation of genetic testing that has not been more specifically addressed by criteria in another policy.

- I. Oncology [algorithmic testing](#)\* is considered **medically necessary** when:
  - A. The member/enrollee has a suspected or confirmed neoplasm and/or malignancy, **AND**
  - B. The test has [clinical validity](#), as demonstrated by accurately determining diagnostic, prognostic or clinical information for a disease, **AND**
  - C. The test has [clinical utility](#), as demonstrated by at least one of the following:
    1. The test will determine if a particular therapeutic intervention is effective (or ineffective) in the member/enrollee, or if a particular intervention may be harmful, **OR**
    2. The test will directly impact the clinical management, **OR**
    3. The test will determine prognosis, **OR**
    4. The test will provide or refine estimates of the natural history, recurrence risk, or the predicted course of the genetic condition.
- II. Oncology [algorithmic testing](#) is considered **investigational** for all other indications.

\*See the Oncology: [Algorithmic testing](#) policy for criteria regarding common [algorithmic tests](#).

[back to top](#)

### General Criteria for Other Genetic Tests

The criteria below is intended for the evaluation of genetic testing that has not been more specifically addressed by criteria in another policy.

- I. Other tests are considered **medically necessary** when:
  - A. The member/enrollee displays relevant clinical features consistent with the intended use of the test, **AND**

- B. The test has [clinical validity](#), as demonstrated by accurately determining diagnostic, prognostic or clinical information for a disease, **AND**
  - C. The test has [clinical utility](#), as demonstrated by at least one of the following:
    - 1. The test will determine if a particular therapeutic intervention is effective (or ineffective) in the member/enrollee, or if a particular intervention may be harmful, **OR**
    - 2. The test will directly impact the clinical management, **OR**
    - 3. The test will determine prognosis, **OR**
    - 4. The test will provide or refine estimates of the natural history, recurrence risk, or the predicted course of the genetic condition, **AND**
  - D. Testing is being performed in a Clinical Laboratory Improvement Amendments (CLIA) approved laboratory.
- II. Other tests are considered **investigational** for all other indications.

[back to top](#)

## DEFINITIONS

1. An **adult-onset condition** is one in which the signs, symptoms, or manifestations of a disease typically begin after a person is age 18 years or older.
2. **Childhood** is the period of development until the 18th birthday.
3. **Germline** pathogenic or likely pathogenic variants are mutations that occur in the egg and sperm cells, also known as the germ cells. These variants are inherited; that is, passed down in families by blood relatives. Most germline mutations do not result in disease.
4. **Multifactorial conditions** are complex conditions that are inherited and may be caused by a combination of the effects of multiple genes or by interactions between genes and the environment.
5. **Close relatives** include first, second, and third degree blood relatives on the same side of the family:
  - a. **First-degree relatives** are parents, siblings, and children
  - b. **Second-degree relatives** are grandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings
  - c. **Third-degree relatives** are great grandparents, great aunts, great uncles, great grandchildren, and first cousins

6. **Clinical validity**, according to the National Institutes of Health-Department of Energy (NIH-DOE) Task Force on Genetic Testing, describes the accuracy with which a test identifies a particular clinical condition. The components of measuring clinical validity are:
  - a. **Sensitivity**: among people with a specific condition, the proportion who have a positive test result
  - b. **Specificity**: among people who do not have the condition, the proportion who have a negative test result
  - c. **Positive predictive value**: among people with a positive test result, the proportion of people who have the condition
  - d. **Negative predictive value**: among people with a negative test result, the proportion who do not have the condition
7. **Clinical utility** refers to the risks and benefits resulting from genetic test use. The most important considerations in determining clinical utility are: (1) whether the test and any subsequent interventions lead to an improved health outcome among people with a positive test result; and (2) what risks occur as a result of testing.
8. An **algorithmic test** is one that combines biomarkers and clinical data into an algorithm to generate a disease risk assessment, prognostic result, or clinical recommendation for treatment.

[back to top](#)

## BACKGROUND AND RATIONALE

### General Criteria for Known Familial Variant Analysis

#### *Genetic Support Foundation*

The Genetic Support Foundation's Genetics 101 information on inheritance patterns says the following about testing for familial pathogenic variants:

“Genetic testing for someone who may be at risk for an inherited disease is always easier if we know the specific genetic cause. Oftentimes, the best way to find the genetic cause is to start by testing someone in the family who is known or strongly suspected to have the disease. If their testing is positive, then we can say that we have found the familial pathogenic (harmful) variant. We can use this as a marker to test other members of the family to see who is also at risk.”

#### *National Society of Genetic Counselors (NSGC)*

The National Society of Genetic Counselors updated a position statement (2017) regarding the genetic testing of minors for adult-onset conditions, stating the following:



“[NSGC] encourages deferring predictive genetic testing of minors for adult-onset conditions when results will not impact childhood medical management or significantly benefit the child. Predictive testing should optimally be deferred until the individual has the capacity to weigh the associated risks, benefits, and limitations of this information, taking his/her circumstances, preferences, and beliefs into account to preserve his/her autonomy and right to an open future.”

### **General Criteria for Targeted Carrier Screening**

*American College of Obstetricians and Gynecologists (ACOG)*

ACOG published practice bulletin No. 690 (March 2017, reaffirmed 2023), which includes the following recommendations related to carrier screening:

- Given the multitude of conditions that can be included in expanded carrier screening panels, the disorders selected for inclusion should meet several of the following consensus-determined criteria: have a carrier frequency of 1 in 100 or greater, have a well-defined phenotype, have a detrimental effect on quality of life, cause cognitive or physical impairment, require surgical or medical intervention, or have an onset early in life. Additionally, screened conditions should be able to be diagnosed prenatally and may afford opportunities for antenatal intervention to improve perinatal outcomes, changes to delivery management to optimize newborn and infant outcomes, and education of the parents about special care needs after birth.
- Carrier screening panels should not include conditions primarily associated with a disease of adult onset. (p. e36)

ACOG published practice bulletin No. 691 (March 2017, reaffirmed 2023), which includes the following recommendations related to carrier screening:

- Information about carrier screening should be provided to every pregnant woman.
- Carrier screening and counseling ideally should be performed before pregnancy because this enables couples to learn about their reproductive risk and consider the most complete range of reproductive options. A patient may decline any or all screening.
- When an individual is found to be a carrier for a genetic condition, his or her relatives are at risk of carrying the same mutation. The patient should be encouraged to inform his or her relatives of the risk and the availability of carrier screening.
- If an individual is found to be a carrier for a specific condition, the patient’s reproductive partner should be offered testing in order to receive informed genetic counseling about potential reproductive outcomes.
- If both partners are found to be carriers of a genetic condition, genetic counseling should be offered. (p. 597)

### **General Criteria for Single Gene or Multigene Panel Analysis**

*American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP)*

- The ACMG and AMP released criteria on the types and severity of mutations, which are as follows:
  - **Very strong evidence of pathogenicity:** Null variants in a gene where loss of function (LOF) is a known mechanism of disease. The guidelines note to use caution in genes where LOF is not a mechanism, if LOF variants are at the 3' end, if exon skipping occurs, and if multiple transcripts are present.
  - **Strong:** Amino acid change to a pathogenic version, de novo mutations, established studies supporting a damaging gene or gene product, or if the prevalence of the variant is increased in affected individuals compared to healthy controls. The guidelines note to be careful of changes impacting splicing and if only the paternity has been confirmed.
  - **Moderate:** Located in a mutational hot spot or well-established functional domain without a benign variant, absent from controls in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium, detected in trans with pathogenic variants for a recessive disorder, protein length changes, novel missense changes where a different missense change has been pathogenic before, and a possible de novo mutation.
  - **Supporting:** Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease, missense variant in a gene with low rate of benign missense variation, if the mutation has evidence that it is deleterious, or if the patient's phenotype is highly specific for disease with a single genetic cause. (p. 412)

*American College of Medical Genetics and Genomics (ACMG)*

The American College of Medical Genetics and Genomics Board of Directors (2015) published a position statement regarding the clinical utility of genetic and genomic services that stated the following regarding individuals and situations where a definitive genetic diagnosis has clinical utility:

Clinical Utility for Individual Patients

- Situations in which definitive diagnosis specifically informs causality, prognosis, and treatment
- Newborn screening for conditions recommended by the Secretary's Discretionary Advisory Committee on Heritable Disorders of Newborns and Children
- The discovery of medically actionable secondary findings in the course of genomic testing that have associated treatments that improve/affect outcome
- Patients with complex and often poorly understood clinical disorders such as autism spectrum disorders and intellectual disability
- Patients with rare disorders, including those diagnosed by chromosome analysis (such as karyotype) or microarray

- Patients with genetic conditions such that definitive and specific guidance regarding prognosis and medical management is not yet available

### Clinical Utility for Families

- Enables at-risk family members to obtain testing to determine whether they carry a causative mutation, offering the possibility for early intervention. This clinical utility is independent of whether the affected family member has benefited directly from this diagnosis.
- Enables specific and informed reproductive decision-making and family planning.
- Brings resolution to the costly (in terms of both psychosocial and financial contexts) and wasteful (for the medical system at large) diagnostic odyssey that is often pursued in a quest to establish a diagnosis. There are countless examples of economic and psychological costs to the health-care system and to patients and families during the quest to obtain a diagnosis.
- Enables involvement in disease support groups and other types of social support for families.

### Clinical Utility for Society

- Understanding the etiology of disease and increased accrual into clinical trials will propel research, benefitting society as a whole.
- Many genetic disease risks can be identified decades before the time when benefits accrue to the individual or their family members. In the current health-care environment, cost-effectiveness often is measured by return on investment to payers and is measured over much shorter time periods, despite long-term benefits to population health. (p. 506)

### *National Society of Genetic Counselors (NSGC)*

The National Society of Genetic Counselors released a position statement (2017) (reaffirmed 2020 and 2023) endorsing the use of multi-gene panels when clinically warranted and appropriately applied, stating the following:

“These tests can provide a comprehensive and efficient route to identifying the genetic causes of disease. Before ordering a multi-gene panel test, providers should thoroughly evaluate the analytic and clinical validity of the test, as well as its clinical utility. Additional factors to consider include, but are not limited to: clinical and family history information, gene content of the panel, limitations of the sequencing and informatics technologies, and variant interpretation and reporting practices.

Panels magnify the complexities of genetic testing and underscore the value of experts, such as genetic counselors, who can educate stakeholders about appropriate utilization of the technology to mitigate risks of patient harm and unnecessary costs to the healthcare system. NSGC supports straightforward and transparent pricing so that patients, providers, laboratories, and health plans can easily weigh the value of genetic testing in light of its cost.”

The National Society of Genetic Counselors updated a position statement (2017) regarding the

genetic testing of minors for adult-onset conditions, stating the following:

“[NSGC] encourages deferring predictive genetic testing of minors for adult-onset conditions when results will not impact childhood medical management or significantly benefit the child. Predictive testing should optimally be deferred until the individual has the capacity to weigh the associated risks, benefits, and limitations of this information, taking his/her circumstances, preferences, and beliefs into account to preserve his/her autonomy and right to an open future.”

*American Academy of Pediatrics (AAP) and American College of Medical Genetics and Genomics (ACMG)*

“Decisions about whether to offer genetic testing and screening should be driven by the best interest of the child.” (p. 234)

“The AAP and the ACMG do not support routine carrier testing or screening for recessive conditions when carrier status has no medical relevance during minority”. (p. 236)

“Predictive genetic testing for adult onset conditions generally should be deferred unless an intervention initiated in childhood may reduce morbidity or mortality”. (p. 238)

## General Criteria for Tumor Biomarker Analysis

*National Comprehensive Cancer Network*

The NCCN guidelines for Occult Primary (1.2024) recommend somatic/tumor molecular genetic testing for patients who are candidates for anti-cancer therapy in order to identify uncommon genetic changes within the tumors (p. OCC-1).

*Hayes, et al*

In an article by Hayes, et al (2020), the authors state that while there is no strict definition of clinical utility for tumor biomarker tests (TBT), there are several factors that should be considered when deciding on the overall clinical utility (p. 238):

- (1) What is the intended use of the tumor biomarker test?
- (2) What are the endpoints that are used to determine clinical utility?
- (3) How substantial does the difference in endpoints between groups defined by the TBT need to be to determine therapeutic strategies?
- (4) What is the risk tolerance of the stakeholders?
- (5) Who are the stakeholders that make the decision?

The authors note that “for a TBT to have clinical utility, it must have high analytical validity and be shown, with high levels of evidence, to improve outcomes compared with if the TBT results

are not known. A pragmatic determination of clinical utility is dependent on several factors, including what end point is considered, how large the difference in that end point must be to apply the TBT, the level of evidence that exists to support the decision to apply the TBT, and the risk tolerance of whichever stakeholder makes the decision to apply it. None of these factors can be the absolute determinant, but they must be included in the deliberations of whether a TBT does or does not have clinical utility.” (p. 239)

*Burke, et al*

This article from the NIH defines clinical validity and clinical utility, provides examples, and considers the implications of these test properties for clinical practice. When a test is used diagnostically, clinical validity measures the accuracy with which the test identifies a person with the clinical condition in question. The positive and negative predictive values of the test are important measures of clinical validity. These measures allow the clinician to determine how reliably the test can confirm or refute a suspected diagnosis. (p. 2-3)

Table 9.15.1 (p. 12) describes the test properties of measuring clinical validity as follows:

- Sensitivity: Among people with a specific condition, the proportion who have a positive test result
- Specificity: Among people who do not have the condition, the proportion who have a negative test result
- Positive predictive value: Among people with a positive test result, the proportion who have the condition
- Negative predictive value: Among people with a negative test result, the proportion who do not have the condition

### **General Criteria for Oncology Algorithmic Tests**

*Centers for Disease Control and Prevention (CDC)*

The CDC’s Office of Public Health Genomics developed the ACCE Model (Analytic Validity, Clinical Validity, Clinical Utility, and Ethical/Legal/Social Implications), which is a clinical framework in which to evaluate a genetic test. The ACCE model process “...is composed of a standard set of 44 targeted questions that address disorder, testing, and clinical scenarios, as well as analytic and clinical validity, clinical utility, and associated ethical, legal, and social issues.” A complete list of the 44 targeted questions referenced can be found at the following website: [https://www.cdc.gov/genomics/gtesting/acce/acce\\_proj.htm](https://www.cdc.gov/genomics/gtesting/acce/acce_proj.htm)

*Burke, et al*

This article from the NIH defines clinical validity and clinical utility, provides examples, and considers the implications of these test properties for clinical practice. When a test is used diagnostically, clinical validity measures the accuracy with which the test identifies a person with the clinical condition in question. The positive and negative predictive values of the test are important measures of clinical validity. These measures allow the clinician to determine how reliably the test can confirm or refute a suspected diagnosis. (p. 2-3)

Table 9.15.1 (p. 12) describes the test properties of measuring clinical validity as follows:

- Sensitivity: Among people with a specific condition, the proportion who have a positive test result
- Specificity: Among people who do not have the condition, the proportion who have a negative test result
- Positive predictive value: Among people with a positive test result, the proportion who have the condition
- Negative predictive value: Among people with a negative test result, the proportion who do not have the condition

Clinical utility refers to the risks and benefits resulting from genetic test use. The most important considerations in determining clinical utility are: (1) whether the test and any subsequent interventions lead to an improved health outcome among people with a positive test result; and (2) what risks occur as a result of testing. (p. 6)

*The American Association for Clinical Chemistry (AACC)*

An online article released from the AACC in 2018 defined and reviewed the use of multianalyte assays with algorithmic analyses (MAAAs). They state:

“...these tests combine results from two or more biochemical or molecular markers, along with patient demographics and clinical information, into an algorithm to generate diagnostic, prognostic, or predictive information for a disease. In cases where single biomarker tests lack acceptable clinical sensitivity and specificity, MAAAs can improve or refine disease detection through individualized risk assessment.

Incorporating multiple biochemical or molecular analytes into algorithms with or without clinical information allows for a personalized risk assessment of a patient’s disease.”

## **General Criteria for Other Genetic Tests**

*Centers for Disease Control and Prevention (CDC)*

The CDC’s Office of Public Health Genomics developed the ACCE Model (Analytic Validity, Clinical Validity, Clinical Utility, and Ethical/Legal/Social Implications), which is a clinical framework in which to evaluate a genetic test. The ACCE model process “...is composed of a standard set of 44 targeted questions that address disorder, testing, and clinical scenarios, as well as analytic and clinical validity, clinical utility, and associated ethical, legal, and social issues.” A complete list of the 44 targeted questions referenced can be found at the following website: [https://www.cdc.gov/genomics/gtesting/acce/acce\\_proj.htm](https://www.cdc.gov/genomics/gtesting/acce/acce_proj.htm)

*Burke, et al*

This article from the NIH defines clinical validity and clinical utility, provides examples, and considers the implications of these test properties for clinical practice. When a test is used diagnostically, clinical validity measures the accuracy with which the test identifies a person with

the clinical condition in question. The positive and negative predictive values of the test are important measures of clinical validity. These measures allow the clinician to determine how reliably the test can confirm or refute a suspected diagnosis. (p. 2-3)

Table 9.15.1 (p. 12) describes the test properties of measuring clinical validity as follows:

- Sensitivity: Among people with a specific condition, the proportion who have a positive test result
- Specificity: Among people who do not have the condition, the proportion who have a negative test result
- Positive predictive value: Among people with a positive test result, the proportion who have the condition
- Negative predictive value: Among people with a negative test result, the proportion who do not have the condition

Clinical utility refers to the risks and benefits resulting from genetic test use. The most important considerations in determining clinical utility are: (1) whether the test and any subsequent interventions lead to an improved health outcome among people with a positive test result; and (2) what risks occur as a result of testing. (p. 6)

[back to top](#)

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Converted corporate to local policy.	09/23	11/27/23



Reviews, Revisions, and Approvals	Revision Date	Approval Date
<p><b>Semi-annual review. Updated name to “CONCERT GENETIC TESTING: GENERAL APPROACH TO GENETIC AND MOLECULAR TESTING”.</b> Overview, coding, reference-table, background and references updated. Throughout policy: replaced “coverage criteria” with “criteria. Removed Policy Reference Table. For Single Gene or Multigene Panel Analysis: removed “conventional diagnostic testing” and added “clinical evaluation and other standard...”. Added “General Tumor Biomarker Analysis...”. Added “Oncology Algorithmic Tests...”. Added “Other Tests”. For Notes and Definitions: added “9. Clinical validity, according to the National...”; added “10. Clinical utility refers to the risks...”; added “11. An algorithmic test is one that combines...”. For Background and Rationale; under Known Familial Variant Analysis: added “National Society of Genetic Counselors (NSGC)...”; added “General Tumor Biomarker Analysis...”; added “Oncology Algorithmic Test...”; added “Other Genetic Tests...”.</p>	12/23	2/27/24
<p>Semi-annual review. In General Criteria for Oncology Algorithmic Tests criteria, minor expansion of criteria to be consistent with guidelines (added “suspected neoplasm and/or malignancy” to the coverage criteria, previously only allowed for confirmed neoplasm). Criteria set name changed (former name: Oncology Algorithmic Tests). Updated coverage criteria assessing for clinical validity and utility. In General Criteria for Known Familial Variant Analysis for a Genetic Condition criteria, several Known Familial Variant criteria moved to policy “Genetic Testing: General Approach to Genetic and Molecular Testing” to consolidate criteria for known familial variant tests. Removed subjective criteria point: “The genetic condition is associated with a significant health problem or problems.” In Single Gene or Multigene Panel Analysis criteria, updated coverage criteria assessing for clinical validity and utility. Removed subjective criteria point: “Genetic testing for the suspected genetic condition has been scientifically validated to improve health outcomes (i.e., the test has been shown to have clinical utility).” In General Criteria for Targeted Carrier Screening criteria, moved criteria FROM policy “Genetic Testing: Prenatal and Preconception Carrier Screening” to align with other general coverage criteria tests. In General Criteria for Tumor Biomarker Analysis criteria, criteria set name changed (former name: General Tumor Biomarker Analysis). Updated coverage criteria assessing for clinical validity and utility. In General Criteria for Other Tests criteria, criteria set name changed (former name: Other Tests). Updated coverage criteria assessing for clinical validity and utility. Minor rewording for clarity throughout. Coding, reference-table, background and references updated.</p>	06/24	8/19/24

**REFERENCES**

1. ACMG Board of Directors. Clinical utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2015;17(6):505-507. doi:10.1038/gim.2015.41
2. “Genetic Testing of Minors for Adult-Onset Conditions”. Position Statement from National Society of Genetic Counselors. <https://www.nsgc.org/Policy-Research-and->



- [Publications/Position-Statements/Position-Statements/Post/genetic-testing-of-minors-for-adult-onset-conditions](#). Released February 15, 2017. Updated April 18, 2018.
3. Ross LF, Saal HM, David KL, Anderson RR; American Academy of Pediatrics; American College of Medical Genetics and Genomics. Technical report: Ethical and policy issues in genetic testing and screening of children [published correction appears in *Genet Med*. 2013 Apr;15(4):321. Ross, Laine Friedman [corrected to Ross, Lainie Friedman]]. *Genet Med*. 2013;15(3):234-245. doi:10.1038/gim.2012.176
  4. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424. doi:10.1038/gim.2015.30
  5. “Use of Multi-Gene Panel Testing.” Position Statement from National Society of Genetic Counselors. <https://www.nsgc.org/Policy-Research-and-Publications/Position-Statements/Position-Statements/Post/use-of-multi-gene-panel-tests>. Released March 14, 2017. Reaffirmed 2020 and 2023
  6. Genetic Support Foundation. Genetics 101 Inheritance Patterns: Familial Pathogenic Variant. Accessed 10/4/2022. <https://geneticsupportfoundation.org/genetics-101/#>
  7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Occult Primary. Version 1.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/occult.pdf](https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf)
  8. ACCE Model Process for Evaluating Genetic Tests. (2010, December 28). Centers for Disease Control and Prevention. Accessed 2023, June 5. <https://www.cdc.gov/genomics/gtesting/acce/index.htm>
  9. Hayes DF. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. *J Clin Oncol*. 2021;39(3):238-248. doi:10.1200/JCO.20.01572
  10. Burke W. Genetic tests: clinical validity and clinical utility. *Curr Protoc Hum Genet*. 2014;81:9.15.1-9.15.8. Published 2014 Apr 24. doi:10.1002/0471142905.hg0915s81
  11. Wang HY, Chen CH, Shi S, et al. Improving Multi-Tumor Biomarker Health Check-up Tests with Machine Learning Algorithms. *Cancers (Basel)*. 2020;12(6):1442. Published 2020 Jun 1. doi:10.3390/cancers12061442
  12. Turner, KA, Algeciras-Schimmich, A. Multianalyte Assays with Algorithmic Analysis in Women’s Health. *Association for Diagnostics and Laboratory Medicine (ADLM)*. 2018. <https://www.aacc.org/cln/articles/2018/july/multianalyte-assays-with-algorithmic-analysis-in-womens-health>
  13. Committee Opinion No. 690 (Reaffirmed 2023: Carrier Screening in the Age of Genomic Medicine. *Obstet Gynecol*. 2017;129(3):e35-e40. doi:10.1097/AOG.0000000000001951
  14. Committee Opinion No. 691 Summary: Carrier Screening for Genetic Conditions. *Obstet Gynecol*. 2017 (Reaffirmed 2023);129(3):597-599. doi:10.1097/AOG.0000000000001948

[back to top](#)

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program

approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollees and their representatives agree to be bound by such terms and conditions by providing services to member/enrollees and/or submitting claims for payment for such services.

©2023 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained

herein. Louisiana Healthcare Connections is a registered trademarks exclusively owned by Louisiana Healthcare Connections.